Cision Vision

What Cision Vision does

Cision Vision Inc. is a private medical device company founded in 2020 by imaging scientist Jeremy Li, PhD and MIT professor Angela Belcher, PhD, headquartered in San Mateo, California. The company develops and commercializes Shortwave Infrared (SWIR) imaging technology operating in the 1000-2000 nm wavelength range, which exploits natural differences in water and lipid content to provide real-time, radiation-free, contrast-agent-free visualization of tissue structures. Its commercial product, the Cision InVision 1.0, is a U.S. FDA Class 1 pathology imaging device (GMDN 65539) that enhances lymph node detection during grossing by displaying lymph nodes as dark areas against bright surrounding fat tissue, requiring no workflow change for pathologists and pathologists' assistants. Cision Vision serves clinical pathology laboratories and hospital oncology departments, with 5 of the top 10 U.S. News Best Oncology Hospitals reported as customers.

The company's revenue model centers on direct hardware sales of the InVision device to enterprise pathology labs and hospitals via a field sales motion, supplemented by the Visionary Program (early-adopter pricing, extended demos, and free upgrades to the upcoming VisionBoard device) and a SaaS-like software layer (Enlight Software) bundled with the hardware. The company is also developing an AI-powered intraoperative Surgical SWIR Imaging System under a five-year, up to $22.3 million ARPA-H Precision Surgical Interventions Program award (August 2024) in collaboration with Stanford Medicine, Johns Hopkins University, Endeavor Health, and the University of Notre Dame. Supporting ecosystem assets include the Cision Academy education platform, ISO 13485 and FDA 21 CFR Part 820 quality system certifications, and an exclusive medical-application license to MIT-originated SWIR imaging patents. In March 2025, Cision Vision expanded into Europe with a distribution partnership with Casa Alvarez, launching InVision in Spain. The company has been funded primarily through non-dilutive grants (SBIR 2021, NSF 2021, ARPA-H 2024) rather than traditional venture capital.

Name

Cision Vision

Legal name

Cision Vision Inc.

Website

https://cisionvision.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Cision Vision is a private medical device company that develops Shortwave Infrared (SWIR) imaging systems for clinical pathology and oncology surgery. Its FDA Class 1 InVision device enhances lymph node detection in pathology labs, serving top U.S. oncology hospitals.

Ownership category

akta.pro rank

Product category

Medical Imaging Equipment

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

akta.pro secondary industries

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Medical Imaging AI (HDAAAEAH)

Keywords

• Shortwave infrared imaging
• Pathology imaging devices
• Surgical oncology imaging
• Lymph node detection
• Intraoperative imaging systems

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. InVision Device Hardware Sales: Primary revenue stream from selling the InVision imaging device to pathology labs and hospitals. One-time hardware purchase model typical for medical imaging equipment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Cision Vision develops and sells the Cision InVision 1.0, an FDA Class 1 shortwave infrared (SWIR) imaging device used by pathologists and pathologists' assistants to enhance lymph node detection during grossing without changing existing workflow. The company is also developing an AI-powered intraoperative SWIR/hyperspectral imaging system for real-time critical structure identification during cancer surgery, supported by a $22.3M ARPA-H grant. Revenue is generated primarily through one-time hardware sales of the InVision device to pathology labs and hospital oncology departments.

Product overview

Cision Vision offers a portfolio of medical imaging products centered on proprietary shortwave infrared (SWIR) technology. The core commercial product is the Cision InVision 1.0, an FDA Class 1 pathology imaging device that enhances lymph node detection during grossing through real-time SWIR contrast imaging. The Enlight Software provides the imaging algorithms for the InVision hardware. The upcoming VisionBoard represents the next generation of the imaging platform. In the surgical domain, the company is developing an AI-powered intraoperative SWIR/Hyperspectral imaging system (part of the ARPA-H Precision Surgical Interventions Program) to help surgeons visualize critical anatomy in real-time. Supporting services include Cision Academy (educational resources including Journal Club and expert learning) and the Visionary Program (early adopter and study partner opportunities).

Differentiator

Problem solved

Functional benefit

Brands

• InVision: Cision InVision is a shortwave infrared imaging device for pathology that helps practitioners perform lymph node searches with enhanced efficiency and accuracy. It is based on breakthrough imaging technologies invented at MIT and depicts lymph nodes in high contrast against surrounding adipose tissue in real-time without radiation or contrast media.
• VisionBoard

Products and services

• Cision InVision 1.0 Pathology Imaging System A US FDA Class 1 phase contrast microscope (GMDN: 65539) that uses shortwave infrared (SWIR) imaging technology to enhance lymph node detection during pathology grossing. The device displays lymph nodes as dark areas and surrounding fat tissue as bright areas in real-time, enabling pathologists and pathologists' assistants to locate lymph nodes with higher efficiency and accuracy without changing their existing workflow or using contrast agents.
• Surgical SWIR/Hyperspectral Imaging System (ARPA-H PSI Program) An AI-powered intraoperative imaging system under development that uses shortwave infrared and hyperspectral imaging to help surgeons visualize blood vessels, nerves, and lymphatic structures in real time during surgery. Aims to improve critical anatomy visualization during cancer surgery without administering dyes, potentially reducing unintended tissue damage and repeat procedures. Currently undergoing development and evaluation, not yet FDA-approved for surgical applications.

Quantifiable outcome

• Time Magazine Best Inventions 2023 recognition validates the technology's breakthrough potential

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature2 records

Partnerships

Four partnerships are on record, tiered core.

• Stanford MedicinecoreStrategic or Co-development Partner · 1 January 2024Stanford Medicine is a key research partner in the 5-year project funded by ARPA-H. The collaboration focuses on clinical validation of SWIR imaging technology for enhanced lymph node detection and surgical applications.
• Johns Hopkins UniversitycoreStrategic or Co-development Partner · 1 January 2024Johns Hopkins University is a research partner in the ARPA-H funded 5-year project, contributing to clinical validation studies of SWIR imaging technology in pathology and surgical applications.
• Endeavor HealthcoreStrategic or Co-development Partner · 1 January 2024Endeavor Health is a clinical partner in the ARPA-H funded 5-year collaborative project, providing hospital-based clinical settings for validation of SWIR imaging technology.
• University of Notre DamecoreStrategic or Co-development Partner · 1 January 2024University of Notre Dame is an academic research partner in the ARPA-H funded 5-year project, contributing research expertise to the development and validation of SWIR imaging technology.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cision-vision

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cision Vision